TARO-PRAVASTATIN 40 MG
PRAVASTATIN SODIUM : 40 MG · DIN 02284456 · SUN PHARMA CANADA INC
Health Canada status: MARKETED
What is TARO-PRAVASTATIN?
TARO-PRAVASTATIN 40 MG contains PRAVASTATIN SODIUM : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02284456, held by SUN PHARMA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Dec-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-PRAVASTATIN used for?
Adjunct to diet for primary hypercholesterolemia. Primary prevention of coronary events. Secondary prevention of cardiovascular events (reduce mortality, MI, stroke, revascularization).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02284456 |
|---|---|
| Brand name | TARO-PRAVASTATIN |
| Generic / active ingredient | PRAVASTATIN SODIUM : 40 MG |
| Manufacturer | SUN PHARMA CANADA INC |
| Strength | 40 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA03 PRAVASTATIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Dec-2022 |
How is it administered?
Adjunct to diet. Initially 10-20 mg once daily at bedtime. Range 10-40 mg/day. Elderly and renally impaired should start at the lowest dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists page 20, but text ends earlier).
How is it supplied?
Not explicitly detailed in provided text (mentions 10, 20, 40 mg strengths).
Contraindications
Hypersensitivity to drug; active liver disease; unexplained persistent elevations of serum transaminases (>3x ULN); pregnancy and nursing women.
Warnings and precautions
Muscle effects (myopathy, rhabdomyolysis); liver dysfunction (monitor transaminases); interstitial lung disease; endocrine function changes; risk of increased HbA1c/glucose levels.
What can be used instead?
Other Canadian products sharing ATC code C10AA03 PRAVASTATIN. 51 of 126 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-PRAVASTATIN | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440644 |
| ACH-PRAVASTATIN | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440652 |
| ACH-PRAVASTATIN | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440660 |
| AG-PRAVASTATIN | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476142 |
| AG-PRAVASTATIN | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476150 |
| AG-PRAVASTATIN | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476169 |
| APO-PRAVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02243506 |
| APO-PRAVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02243507 |
| APO-PRAVASTATIN | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 02243508 |
| AURO-PRAVASTATIN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02458977 |
Who else supplies PRAVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PRAVASTATIN appears in 291 registered pack listings across 8 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.